Dyspnoea in the GLOBAL LEADERS trial

Affiliations

¹ Cardiology Department, Central Defense Hospital, Alcalá University, 28049 Madrid, Spain. Electronic address: docalcala@hotmail.com.
² Cardiology Department, Ramón y Cajal Hospital, Alcalá University, 28049 Madrid, Spain.

Comment

David Martí et al. Lancet. 2019.

. 2019 Jun 15;393(10189):2393.

doi: 10.1016/S0140-6736(19)30697-X.

¹ Cardiology Department, Central Defense Hospital, Alcalá University, 28049 Madrid, Spain. Electronic address: docalcala@hotmail.com.
² Cardiology Department, Ramón y Cajal Hospital, Alcalá University, 28049 Madrid, Spain.

No abstract available

Comment in

Dyspnoea in the GLOBAL LEADERS trial - Authors' reply.
Jüni P, Vranckx P, Valgimgli M, Serruys P, Windecker S; GLOBAL LEADERS Investigators. Jüni P, et al. Lancet. 2019 Jun 15;393(10189):2393-2394. doi: 10.1016/S0140-6736(19)30685-3. Lancet. 2019. PMID: 31204678 No abstract available.

Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial.
Vranckx P, Valgimigli M, Jüni P, Hamm C, Steg PG, Heg D, van Es GA, McFadden EP, Onuma Y, van Meijeren C, Chichareon P, Benit E, Möllmann H, Janssens L, Ferrario M, Moschovitis A, Zurakowski A, Dominici M, Van Geuns RJ, Huber K, Slagboom T, Serruys PW, Windecker S; GLOBAL LEADERS Investigators. Vranckx P, et al. Lancet. 2018 Sep 15;392(10151):940-949. doi: 10.1016/S0140-6736(18)31858-0. Epub 2018 Aug 27. Lancet. 2018. PMID: 30166073 Clinical Trial.